

**If you purchased, paid for, and/or provided reimbursement for some or all of the price of one or more of the Prescription Generic Drugs listed in Appendix A to this Notice at any time from May 1, 2009 until December 31, 2019, you could get a payment from a class action settlement.**

*A federal court authorized this Notice. This is not a solicitation from a lawyer.*

PLEASE READ THIS ENTIRE NOTICE CAREFULLY. YOUR RIGHTS MAY BE AFFECTED BY THE PROCEEDINGS IN THIS ACTION WHETHER YOU ACT OR DO NOT ACT. THIS NOTICE ADVISES YOU OF YOUR RIGHTS AND OPTIONS WITH RESPECT TO THIS LITIGATION.

**Para conseguir una notificación en español, llame a 1-877-316-0171 o visite el sitio web:**  
[www.GenericDrugsEndPayerSettlement.com](http://www.GenericDrugsEndPayerSettlement.com)

This is to provide notice of the preliminary approval of a proposed \$275,000,000 Settlement with Defendants Sandoz Inc. and Fougera Pharmaceuticals Inc. (“Sandoz”) in a Lawsuit brought by Consumers and Third-Party Payers (“TPPs”) who were End-Payers (“End-Payer Plaintiffs” or “EPPs”) of the generic drugs listed in Appendix A at the end of this Notice (the “Named Generic Drugs”). The Lawsuit is a group of class actions coordinated under the civil docket *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 in the United States District Court for the Eastern District of Pennsylvania. The Lawsuit claims that generic drug manufacturers, including Sandoz, violated federal and state antitrust laws, consumer protection statutes, and common law, harming competition and causing the End-Payer Settlement Class to overpay for the Named Generic Drugs. Sandoz denies liability. The Court has not decided who is right. No trial has been held.

The proposed settlement does not resolve any of the claims of the Settlement Class against the remaining Defendants and the Lawsuit against those Non-Settling Defendants is ongoing.

- The Court has preliminarily certified an EPP Sandoz Settlement Class (the “Settlement Class”) for settlement purposes only. The class is defined as:

All persons and entities in each of the 50 United States (except Indiana and Ohio), as well as the District of Columbia, Puerto Rico and the U.S. Virgin Islands, that indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price for any Named Generic Drugs, other than for resale, from May 1, 2009 to December 31, 2019.

Excluded from the EPP Sandoz Settlement Class are (a) Defendants, their officers, directors, management, employees, subsidiaries and affiliates; (b) all federal governmental entities; (c) all state governmental entities (except for cities, towns, municipalities, counties and other local governmental entities with self-funded prescription drug plans, all of which are included in the class); (d) all governmental Medicaid agencies, private Medicaid managed care organizations, and consumers who were covered by Medicaid for their purchases of Named Generic Drugs; and (e) Judges assigned to this case and any members of their immediate families. For the avoidance of doubt, the class does not include (i) persons or entities who only purchased Named Generic Drugs for purposes of resale or directly from Defendants; (ii) fully insured employers to the extent that they use fully-insured plans (*i.e.*, employers that purchased insurance covering 100% of their reimbursement obligation to members); and (iii) pharmacy benefit managers.

Where a putative class member has purchases that meet the definition of the Settlement Class, but also has purchases that fall within one or more of the exclusions above, that putative class member is included in the Settlement Class only with respect to those purchases that meet the definition of the Settlement Class.

- The proposed Settlement provides that Sandoz will pay \$275,000,000 for the benefit of Consumers and TPPs. The Sandoz settlement fund may be reduced under certain circumstances as explained in the Settlement Agreement. As discussed below, the costs of administering the fund and providing notice of the Settlement may be deducted from the fund; and attorneys' fees, expenses and service awards may be deducted from the fund with Court approval.
- Money will be distributed if and after the Court approves the Settlement, likely in conjunction with the proceeds of other settlements, upon Court Order and pursuant to a Court-approved plan for allocating the Sandoz settlement fund to Settlement Class Members (the "Plan of Allocation"). The proposed Plan of Allocation is posted on the website [www.GenericDrugsEndPayerSettlement.com](http://www.GenericDrugsEndPayerSettlement.com) (the "EPP Settlement Website" or "Settlement Website").
- The Court has scheduled a hearing (the "Final Fairness Hearing") to decide whether to approve the Settlement, the Plan of Allocation, and any requests by EPPs' attorneys for reimbursement of expenses out of the settlement fund. The Final Fairness Hearing is scheduled for **July 23, 2025 at 11:00 a.m.**, before Judge Cynthia M. Rufe at the United States District Court for the Eastern District of Pennsylvania, Courtroom 12-A, 601 Market Street, Philadelphia, PA 19106.
- You do not need to attend the hearing. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court and you may (but are not required to) hire your own attorney to appear in court for you at your own expense. Your Notice must be received by **May 9, 2025**.
- The deadlines in this Notice, and the date and time of the hearing, may be amended by Court Order. Check the Settlement Website for updates. You may also register on the Settlement Website to receive updates by mail or email.

## YOUR LEGAL RIGHTS AND OPTIONS

<b>STAY IN THE SETTLEMENT CLASS</b>	<p>You do not need to do anything now to retain your right to stay in the Settlement Class and/or seek a share of the proposed Settlement.</p> <p>You may register on the Settlement Website for settlement-related updates. Then, if the Court decides to give the proposed Settlement final approval, you will be notified by email or mail when a claim form becomes available. Once a claim form is available, you will be able to obtain it from the Settlement Website or by calling 1-877-316-0171.</p>
<b>EXCLUDE YOURSELF FROM THE SETTLEMENT CLASS</b>	<p>You may choose to exclude yourself, or “opt out,” from the Settlement Class. If you decide to exclude yourself, you will not be bound by any future decision in this Lawsuit relating to Sandoz. This is the only option that allows you to ever be part of any lawsuit (other than this Lawsuit) against Sandoz relating to the legal claims against Sandoz in this case.</p> <p>You will not receive a payment from the Settlement if you elect to exclude yourself. Details on how to submit a valid request for exclusion are explained below. Requests for exclusion must be <b>postmarked</b> by <b>May 9, 2025</b>.</p>
<b>STAY IN THE LAWSUIT BUT OBJECT TO THE SETTLEMENT</b>	<p>If you wish to object to all or any part of the proposed Settlement, you may write to the Court about why you do not like the proposed Settlement. Details on how to submit an objection are explained below. Objections must be <b>received</b> by the Court by <b>May 9, 2025</b>.</p> <p>If you wish to attend and speak at the Final Fairness Hearing about your objection, then you must notify the Court that you wish to attend by filing a Notice of Intention to Appear by <b>May 9, 2025</b> (<i>see</i> instructions below).</p>
<b>GET MORE INFORMATION</b>	<p>If you would like to obtain more information about the Lawsuit or the Settlement, you can review the materials on <a href="http://www.GenericDrugsEndPayerSettlement.com">www.GenericDrugsEndPayerSettlement.com</a>, call 1-877-316-0171, send questions to the Notice Administrator at <a href="mailto:info@GenericDrugsEndPayerSettlement.com">info@GenericDrugsEndPayerSettlement.com</a>, and/or attend the Final Fairness Hearing.</p>

**THESE RIGHTS AND OPTIONS – AND THE DEADLINES TO EXERCISE THEM – ARE EXPLAINED IN THIS NOTICE.**

# TABLE OF CONTENTS

## WHAT THIS NOTICE CONTAINS

<b>BASIC INFORMATION .....</b>	<b>PAGE 5</b>
1. Why did I receive notice?	
2. What is this lawsuit about?	
3. What is a class action?	
4. Who are the Defendants in this lawsuit?	
5. Why is there a Settlement?	
<b>WHO IS IN THE SETTLEMENT CLASS AND SETTLEMENT.....</b>	<b>PAGE 7</b>
6. Am I part of the Settlement Class and the Settlement?	
7. Can I request to be excluded from the Settlement Class?	
8. What is the legal significance of excluding myself?	
9. If I don't exclude myself, can I sue Sandoz later?	
10. What happens if I do nothing?	
<b>THE SETTLEMENT'S BENEFITS .....</b>	<b>PAGE 10</b>
11. What does the Settlement provide?	
12. What claims am I settling?	
13. How can I get a payment from the Settlement?	
14. How much will my payment be?	
15. When would I get my payment?	
<b>THE LAWYERS REPRESENTING THE SETTLEMENT CLASS .....</b>	<b>PAGE 12</b>
16. Do I have a lawyer in this case?	
17. How will the lawyers be paid?	
<b>OBJECTING TO THE SETTLEMENT .....</b>	<b>PAGE 13</b>
18. If I don't like the Settlement, how do I tell the Court?	
<b>THE COURT'S FAIRNESS HEARING .....</b>	<b>PAGE 14</b>
19. When will the Court decide whether to approve the Settlement?	
20. Do I have to attend the hearing?	
21. May I speak at the hearing?	
<b>GETTING MORE INFORMATION .....</b>	<b>PAGE 15</b>
22. How do I get more information?	

## BASIC INFORMATION

### 1. WHY DID I RECEIVE NOTICE?

A federal court authorized this Notice. You received Notice because you may have purchased, paid for, and/or provided reimbursement for some or all of the purchase price of one or more Named Generic Drugs at some time from May 1, 2009 until December 31, 2019, and therefore you may be a member of the Settlement Class that was preliminarily certified by the Court. The Settlement Class consists of Consumers (*i.e.*, persons who purchased one or more of the Named Generic Drugs in a pharmacy or by mail-order prescription) and Third-Party Payers (*i.e.*, entities that paid for and/or reimbursed for some or all of the purchase price of one or more of the Named Generic Drugs for use by their members, employees, insureds, participants or beneficiaries). *See* Question 6 for the full class definition and details on who is excluded from the class. You may have received this Notice in error so you should confirm from your own records that you paid for one or more Named Generic Drugs at some time from May 1, 2009 to December 31, 2019 and fall within the Settlement Class definition.

This Notice is only a summary of the Settlement Agreement and your rights. You are encouraged to carefully review the complete Settlement Agreement, which is posted on the Settlement Website.

### 2. WHAT IS THIS LAWSUIT ABOUT?

The Lawsuit is a group of proposed class actions coordinated under the docket *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724. EPPs' class action complaints are available on the Settlement Website. Judge Cynthia M. Rufe, of the United States District Court for the Eastern District of Pennsylvania (the "Court"), is overseeing the Lawsuit and the Settlement.

The EPPs allege that Defendants engaged in an unlawful scheme or schemes to fix, maintain and stabilize prices, rig bids, and engage in market and customer allocation of the Named Generic Drugs in violation of federal and state antitrust laws, consumer protection statutes and common law. EPPs allege that Defendants' conduct harmed competition and caused Settlement Class Members to overpay for the Named Generic Drugs.

All Defendants, including Sandoz, deny that any Settlement Class Member is entitled to damages or other relief. All Defendants, including Sandoz, deny liability as to EPPs' claims. The Settlement between EPPs and Sandoz is not an admission of wrongdoing by any Defendant, including Sandoz.

Following investigation of relevant facts, substantial fact discovery, and arm's length negotiations with Sandoz, EPPs, on behalf of the Settlement Class, entered into the Settlement with Sandoz.

There has been no determination by the Court or a jury that the allegations against Sandoz or the other Defendants have been proven or that, if proven, the conduct caused harm to any Settlement Class Members. No trial has been held.

### 3. WHAT IS A CLASS ACTION?

In a class action, one or more people called “Class Representatives” sue on behalf of others who have similar claims.

The EPP Sandoz Settlement Class Representatives are 1199SEIU Greater New York Benefit Fund; 1199SEIU Licensed Practical Nurses Welfare Fund; 1199SEIU National Benefit Fund; 1199SEIU National Benefit Fund for Home Care Workers; American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan; American Federation of State, County and Municipal Employees District Council 47 Health & Welfare Fund; City of Providence, Rhode Island; Detectives Endowment Association of the City of New York; Hennepin County; Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana; Philadelphia Federation of Teachers Health and Welfare Fund; Self-Insured Schools of California; Sergeants Benevolent Association of the Police Department of the City of New York Health and Welfare Fund; UFCW Local 1500 Welfare Fund; Uniformed Fire Officers Association Family Production Plan Local 854; and United Food & Commercial Workers and Employers Arizona Health & Welfare Trust; Nina Diamond; Ottis McCrary; Valerie Velardi; and Robby Johnson.

The EPPs and those on whose behalf they have sued together constitute the “Settlement Class” or “Settlement Class Members.” Their attorneys are called “Settlement Class Counsel.”

In a class action lawsuit, one court resolves the issues for all Class Members, except for those who exclude themselves (*i.e.*, “opt out”) from the Class. The Court, by Order dated February 19, 2025, has preliminarily determined that the lawsuit between EPPs and Sandoz can proceed as a class action for purposes of determining whether to approve the Settlement. A copy of the Court’s Order may be found on the Settlement Website.

Specifically, the Court has found that, for the purposes of this Settlement:

- The number of Settlement Class Members is so numerous that joining them all into one suit is impracticable;
- Members of the Settlement Class share common legal or factual issues relating to the claims in this case;
- The claims of EPPs are typical of the claims of Settlement Class Members;
- EPPs and Settlement Class Counsel are capable of fairly and adequately protecting the interests of the Settlement Class; and
- Common legal questions and facts predominate over questions affecting only individual members of the Settlement Class, and certification of the Settlement Class is superior to other available methods for the fair and efficient resolution of the claims of the Settlement Class Members.

### 4. WHO ARE THE DEFENDANTS IN THIS LAWSUIT?

The Defendants in this lawsuit are:

- Actavis Elizabeth, LLC
- Actavis Holdco U.S., Inc.
- Actavis Pharma Inc.
- Akorn Sales, Inc.
- Akorn, Inc.
- Alvogen, Inc.

- Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, LLC
- Apotex Corp.
- Ascend Laboratories, LLC
- Aurobindo Pharma USA, Inc.
- Barr Pharmaceuticals, LLC
- Bausch Health Americas, Inc.
- Bausch Health US, LLC
- Breckenridge Pharmaceutical, Inc.
- Camber Pharmaceuticals, Inc.
- Citron Pharma, LLC
- Dava Pharmaceuticals, LLC
- Dr. Reddy's Laboratories, Inc.
- Epic Pharma, LLC
- Fougera Pharmaceuticals Inc.
- G&W Laboratories, Inc.
- Generics Bidco I, LLC
- Glenmark Pharmaceuticals Inc., USA
- Glenmark Pharmaceuticals, Inc.
- Greenstone LLC
- Heritage Pharmaceuticals, Inc.
- Hikma Labs, Inc.
- Hikma Pharmaceuticals USA, Inc.
- Hi-Tech Pharmacal Co., Inc.
- Impax Laboratories, Inc.
- Impax Laboratories, LLC
- Jubilant Cadista Pharmaceuticals Inc.
- Lannett Company, Inc.
- Lupin Pharmaceuticals, Inc.
- Mallinckrodt Inc.
- Mayne Pharma Inc.
- Morton Grove Pharmaceuticals, Inc.
- Mutual Pharmaceutical Company, Inc.
- Mylan Pharmaceuticals, Inc.
- Mylan, Inc.
- Oceanside Pharmaceuticals, Inc.
- Par Pharmaceutical, Inc.
- Perrigo New York Inc.
- Pfizer, Inc.
- Pliva, Inc.
- Sandoz, Inc.
- Sun Pharmaceutical Industries, Inc.
- Taro Pharmaceuticals USA, Inc.
- Teligent, Inc.
- Teva Pharmaceuticals USA, Inc.
- Torrent Pharma Inc.
- Upsher-Smith Laboratories, LLC
- Versapharm Inc.
- West-Ward Columbus, Inc.
- West-Ward Pharmaceuticals Corp.
- Wockhardt USA LLC
- Zydus Pharmaceuticals (USA), Inc.

## 5. WHY IS THERE A SETTLEMENT?

The Court has not decided in favor of EPPs or Sandoz. Instead, both sides have agreed to the Settlement. EPPs and Sandoz were preparing to proceed with the litigation and eventually go to trial, but they have now agreed to the proposed Settlement. By agreeing to this Settlement, the parties avoid the costs and uncertainty of additional discovery, motion practice, and an eventual trial, and if the Settlement is approved by the Court, Settlement Class Members will be eligible to receive a payment from the Settlement. EPPs and Settlement Class Counsel believe that the proposed Settlement is fair, reasonable, adequate, and in the best interests of the Settlement Class.

## WHO IS IN THE SETTLEMENT CLASS AND SETTLEMENT

### 6. AM I PART OF THE SETTLEMENT CLASS AND THE SETTLEMENT?

For settlement purposes only, the Court preliminarily certified the EPP Sandoz Settlement Class on February 19, 2025.

You may be an EPP Sandoz Settlement Class Member if:

You are in any of the 50 United States (except Indiana and Ohio), as well as the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, and indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price for any Named Generic Drugs, other than for resale, from May 1, 2009 to December 31, 2019.

You are **NOT** a member of the EPP Sandoz Settlement Class if you are among any of the following:

- a) Defendants, their officers, directors, management, employees, subsidiaries and affiliates;
- b) all federal governmental entities;
- c) all state governmental entities (except for cities, towns, municipalities, counties and other local governmental entities with self-funded prescription drug plans, all of which are included in the class);
- d) all governmental Medicaid agencies, private Medicaid managed care organizations, and consumers who were covered by Medicaid for their purchases of Named Generic Drugs;
- e) Judges assigned to this case and any members of their immediate families;
- f) persons or entities who only purchased Defendants' Named Generic Drugs for purposes of resale or directly from Defendants;
- g) fully insured employers to the extent that they use fully-insured plans (*i.e.*, employers that purchased insurance covering 100% of their reimbursement obligation to members);  
or
- h) pharmacy benefit managers.

If you made purchases that meet the definition of the Settlement Class, but also made purchases that fall within one or more of the exclusions above, you are included in the Settlement Class only with respect to those purchases that meet the definition of the Settlement Class.

The Named Generic Drugs are listed at the end of this Notice in Appendix A.

If you are not sure whether you are included in the Settlement Class, you may call 1-877-316-0171, review the materials and information posted on the Settlement Website, or contact the attorney or law firm identified in Question 16 below. If you wish to exclude yourself from the Settlement Class, please refer to Question 7.

## 7. CAN I REQUEST TO BE EXCLUDED FROM THE SETTLEMENT CLASS?

Yes, the Court has set **May 9, 2025**, as the deadline for requests for exclusion. To exclude yourself, you must send a letter via email to [info@GenericDrugsEndPayerSettlement.com](mailto:info@GenericDrugsEndPayerSettlement.com) or via First-Class U.S. Mail to:

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation – End-Payer Settlement*

EXCLUSIONS

c/o A.B. Data, Ltd.

P.O. Box 173001

Milwaukee, WI 53217

The letter must include the following:

- (i) For consumers: your name, postal address, email address (if available), and phone number;

PAGE 8 OF 24

QUESTIONS? CALL 1-877-316-0171 OR VISIT [WWW.GENERICDRUGSENDPAYERSETTLEMENT.COM](http://WWW.GENERICDRUGSENDPAYERSETTLEMENT.COM).



- (ii) For TPPs: your entity name, postal address, email address, phone number and Internal Revenue Service Employer Identification Number; and the name, title and signature of your representative submitting the request for exclusion;
- (iii) The name and number of the case: *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 (E.D. Pa.); and
- (iv) A statement, signed by you (if you are a consumer) or an authorized representative (if you are a TPP), that you are a member of the EPP Sandoz Settlement Class and wish to be excluded from the EPP Sandoz Settlement Class.

In addition,

- If you are a self-insured entity that seeks exclusion for its prescription drug plan(s) (or health plan(s) with prescription drug benefits), you must state the name(s) of the plan(s) with specificity.
- If you are an entity that seeks to exclude any claims that were assigned to you by another entity, you must submit documentation showing the assignment and your authority to exclude those claims.
- If you are an entity seeking to exclude another entity, *e.g.*, an insurer seeking to exclude its Administrative Services Only (“ASO”) customers, you must identify with specificity each such entity that you seek to exclude, **and** you must provide a declaration from each entity’s authorized representative, substantially in the form set forth below and executed specifically in connection with this litigation, attesting to your authority to opt the entity’s claims out of the Settlement Class:

Date	
Declarant Name	
Declarant Address	
Declarant Telephone Number	
Declarant Email Address	
Declarant EIN	
<p>Dear Notice Administrator:</p> <p style="text-align: center;">I am [Name and Title of Officer or Employee of Declarant Requesting Exclusion]. [Declarant] has authorized [Submitting Entity] to request exclusion from the EPP Sandoz Settlement Class on [Declarant]’s behalf in the case <i>In re Generic Pharmaceuticals Pricing Antitrust Litigation</i>, Case No. 2:16-MD-02724 (E.D. Pa.).</p> <p>I do so declare under penalty of perjury.</p>	
<p>_____</p> <p>Name/Title of Officer or Employee</p>	<p>_____</p> <p>Date Signed</p>

A SEPARATE EXCLUSION REQUEST MUST BE SUBMITTED BY EACH SETTLEMENT CLASS MEMBER ELECTING TO BE EXCLUDED. ANY SETTLEMENT CLASS MEMBER

INCLUDED IN THE EPP SANDOZ SETTLEMENT CLASS THAT DOES NOT SUBMIT A VALID REQUEST FOR EXCLUSION PROVIDING ALL NECESSARY INFORMATION WILL REMAIN A MEMBER OF THE EPP SANDOZ SETTLEMENT CLASS.

**Your letter requesting exclusion must be EMAILED or POSTMARKED no later than May 9, 2025.**

#### 8. WHAT IS THE LEGAL SIGNIFICANCE OF EXCLUDING MYSELF?

If you exclude yourself from the Settlement Class, you cannot object to any of the terms of the related Settlement Agreement. You also will not be legally bound by anything that happens in the lawsuit between EPPs and Sandoz. This means that you may be able to sue (or continue to sue) Sandoz in the future about the legal issues in this case. If you intend to exclude yourself from the Settlement Class so that you can start or continue your own lawsuit against Sandoz, you should talk to your own lawyer before doing so, because your claims are subject to a statute of limitations, which means that your claims will expire at a certain time (or may already have expired).

#### 9. IF I DON'T EXCLUDE MYSELF, CAN I SUE SANDOZ LATER?

No. If you do not exclude yourself from the Settlement Class, and you have a valid claim, you can share in the Settlement, but you will not be able to start a lawsuit, continue a lawsuit, or be part of any other lawsuit against Sandoz arising from the claims released as part of this Settlement, including claims brought in the case by EPPs against Sandoz. (*See* Question 12 for more information on the released claims.) All of the Court's Orders in the case between EPPs and Sandoz will apply to you and legally bind you. If the Court grants final approval to the proposed Settlement and enters final judgment in the case between EPPs and Sandoz, you will also be bound by the Settlement between EPPs and Sandoz.

#### 10. WHAT HAPPENS IF I DO NOTHING?

If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and be eligible to participate in the Settlement as described in this Notice, if the Settlement is approved. When the time comes for distribution of the settlement fund, you will need to complete, sign, and return a Settlement claim form.

To receive updates on, *e.g.*, whether the Settlement has been approved by the Court, and whether a claim form is available and the deadline for submitting it, you should complete the online registration form on the Settlement Website. When a claim form becomes available, you will be able to obtain it from the Settlement Website or by calling 1-877-316-0171.

### THE SETTLEMENT'S BENEFITS

#### 11. WHAT DOES THE SETTLEMENT PROVIDE?

Pursuant to the terms of the Settlement, Sandoz has paid \$275,000,000.00 in cash to an interest-bearing escrow account for the benefit of EPP Sandoz Settlement Class Members. The Settlement amount may be reduced by a maximum of \$45,000,000.00 under certain circumstances as explained in the Settlement Agreement. Additionally, the following will be deducted from the settlement fund: the costs of settlement notice and administration (up to \$750,000.00), and, if approved by the Court, attorneys' fees (up to one-third of the settlement fund plus interest), litigation expenses (up to \$26,000,000.00), and service awards to the EPP

Sandoz Settlement Class Representatives (up to \$500,000.00 altogether). The settlement fund shall be held in escrow pending final approval of the Settlement. Sandoz has also agreed to cooperate with EPPs in providing information related to EPPs' litigation against the Non-Settling Defendants.

The Settlement Agreement may be terminated if the Court does not approve it. If the Settlement Agreement is terminated, the Lawsuit will proceed against Sandoz as if the Settlement had not been reached.

The complete Settlement Agreement is available on the Settlement Website. This Notice is not meant to, and does not, alter the terms of the Settlement Agreement.

## 12. WHAT CLAIMS AM I SETTLING?

If the Settlement becomes final, the litigation between EPPs and Sandoz will be dismissed with prejudice, and the EPP Sandoz Settlement Class Members will be releasing Sandoz from all claims identified in the Settlement Agreement. Those claims include all claims that have been brought or could have been brought concerning the subject matter of or conduct alleged in EPPs' class action complaints, copies of which are available on the Settlement Website.

The Settlement Agreement specifically describes the released claims, in accurate legal terminology, so read them carefully. For the details of the releases, *see* paragraphs I.B., I.H., I.Q., I.R., and VI. of the Settlement Agreement, which is available on the Settlement Website.

Non-Settling Defendants are **not** part of the proposed Settlement. EPPs' Lawsuit against the Non-Settling Defendants is continuing.

## 13. HOW CAN I GET A PAYMENT FROM THE SETTLEMENT?

The claims process is not open at this time. At a later date, if the Court grants final approval to the Settlement and the proposed Plan of Allocation (*see* "The Court's Fairness Hearing" below) and any resulting appeals are resolved, Settlement Class Counsel will ask the Court for permission to distribute the settlement fund pursuant to the Plan of Allocation.

**If you do not exclude yourself from the Settlement Class, you will need to submit a claim form to request your share of the settlement fund at that time.** To receive updates on when a claim form is available, as well as other updates related to the Settlement, you should complete the online registration form on the Settlement Website. Once a claim form is available, you will be able to obtain it from the Settlement Website or by calling 1-877-316-0171.

## 14. HOW MUCH WILL MY PAYMENT BE?

If the Settlement is approved by the Court, the settlement fund, minus the costs of settlement notice and administration, and minus any court-awarded attorneys' fees, litigation expenses and service awards, will be distributed to Settlement Class Members pursuant to a Plan of Allocation that must be approved by the Court.

You will not be responsible for calculating the amount you may be entitled to receive. The Plan of Allocation provides that you will be paid on a *pro rata* basis in proportion to the amount of money you spent on the Named Generic Drugs from May 1, 2009 through December 31, 2019. In general, those who spent more money on the Named Generic Drugs will get a higher recovery than those who spent less. If less than 100% of the Settlement Class Members send in claim forms, you could get a larger *pro rata* share. Any accrued interest on the settlement fund will be

included, *pro rata*, in the amounts paid to Settlement Class Members. Additional details of how your recovery will be calculated can be found in the proposed Plan of Allocation, which is available on the Settlement Website.

If you exclude yourself from the Settlement Class, you will not receive a share of the Settlement.

#### 15. WHEN WOULD I GET MY PAYMENT?

Settlement Class Counsel will ask the Court for permission to distribute the settlement fund at a later point in time, and once the Court grants permission, the claims process will commence. The timing of Settlement Class Counsel's request to the Court for permission to distribute the settlement fund depends on several factors, including whether and when the Court grants final approval of the Settlement and the proposed Plan of Allocation, whether appeals are taken and how long they take, and the timing of the approval of other settlements in the litigation. In the meantime, EPPs will continue to pursue litigation against the Non-Settling Defendants.

### THE LAWYERS REPRESENTING THE SETTLEMENT CLASS

#### 16. DO I HAVE A LAWYER IN THIS CASE?

The Court appointed Roberta D. Liebenberg and the law firm of Fine, Kaplan and Black, R.P.C., One South Broad Street, 23<sup>rd</sup> Floor, Philadelphia, PA 19107 as lead counsel for the Settlement Class.

#### 17. HOW WILL THE LAWYERS BE PAID?

The Settlement allows for the costs of settlement notice and administration to be deducted from the settlement fund without prior Court approval in an amount not to exceed \$750,000. In addition, the Settlement allows Settlement Class Counsel to ask the Court for the following payments out of the settlement fund: (i) an award of attorneys' fees, not to exceed one-third of the settlement fund (including interest accrued thereon); (ii) reimbursement of litigation expenses; and (iii) service awards to Settlement Class Representatives.

Settlement Class Counsel intend to move for an award of attorneys' fees not to exceed one-third of the settlement fund (including accrued interest); reimbursement for the costs and expenses they advanced in litigating the case not to exceed \$26,000,000; and service awards of up to \$500,000 in total to be paid to Settlement Class Representatives who worked on behalf of the entire Settlement Class to achieve the results of the Settlement. Settlement Class Counsel will file their motion and post it on the Settlement Website, no later than April 9, 2025. A copy of the motion will also be available for viewing at the office of the Clerk of the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106-1797, during normal business hours.

Any payment to the attorneys will be subject to Court approval, and the Court may award less than the requested amount. If the Court grants Settlement Class Counsel's requests, the awarded amounts will be deducted from the settlement fund.

## OBJECTING TO THE SETTLEMENT

### 18. IF I DON'T LIKE THE SETTLEMENT, HOW DO I TELL THE COURT?

If you are a Settlement Class Member and have not excluded yourself, you can object to all or any part of the proposed Settlement, the Plan of Allocation, or the request for attorneys' fees, litigation expenses and service awards. You can give reasons why you think the Court should not approve. The Court will consider your views.

To object to the Settlement, you must file your objection with the Court by sending a letter via First-Class U.S. Mail to the Clerk of Court (mailing address below) with copies to the individuals and addresses listed below. (If an attorney is filing an objection on your behalf, your attorney must comply with the Court's Local Rules, including those that mandate document filings via ECF.)

The objection letter must contain:

- For consumers: your name, postal address, email address (if available), and phone number;
- For TPPs: your entity name, postal address, email address and phone number; and the name, title and signature of your representative submitting the objection;
- The case name and number: *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 (E.D. Pa.);
- The name, postal address, email address, and phone number of your attorney, if you have one;
- A statement on whether you are objecting to the EPP Sandoz Settlement, the proposed Plan of Allocation, and/or the request for attorneys' fees, expenses, and service awards;
- The specific reasons why you object;
- Documentation demonstrating that you are a member of the Settlement Class and/or this statement, followed by your signature (if you are a consumer) or your representative's signature (if you are a TPP): "I declare under penalty of perjury under the laws of the United States of America that [insert your name] is a member of the Settlement Class."; and
- Any supporting materials, papers, or briefs that you want the Court to consider.

**Your objection must be filed with the Court so that it is received by the Court on or before May 9, 2025.**

CLERK OF COURT FOR THE U.S. DIST. CT. FOR THE EASTERN DIST. OF PA	SETTLEMENT CLASS COUNSEL	SETTLING DEFENDANTS' COUNSEL
Clerk of Court, E.D. Pa. 601 Market St. Philadelphia, PA 19106	Roberta D. Liebenberg Jeffrey S. Istvan Fine, Kaplan and Black, R.P.C. One South Broad St., 23 <sup>rd</sup> Floor Philadelphia, PA 19107	Matthew D. Kent Alston & Bird LLP One Atlantic Center 1201 West Peachtree St. Suite 4900 Atlanta, GA 30309

## THE COURT'S FAIRNESS HEARING

The Court will hold a Final Fairness Hearing to decide whether to grant final approval to the Settlement, Plan of Allocation, and request for attorneys' fees, reimbursement of litigation expenses, and service awards. You may attend and, if you have not excluded yourself from the Settlement Class, you may ask to speak, but you do not have to.

### 19. WHEN WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENT?

The Court has scheduled the Final Fairness Hearing for **July 23, 2025 at 11:00 a.m.**, at the United States District Court for the Eastern District of Pennsylvania, Courtroom 12-A, 601 Market Street, Philadelphia, PA 19106.

**The time and date of the Final Fairness Hearing may change without additional mailed notice. For updated information on the hearing, you may check the Settlement Website, or the Court docket in this case, for a fee, through the Court's Public Access to Court Electronic Records (PACER) system at <https://pcl.uscourts.gov>.**

At the Final Fairness Hearing, the Court will consider whether the Settlement and the Plan of Allocation are fair, reasonable and adequate. The Court may also consider the requests by Settlement Class Counsel for attorneys' fees, reimbursement of expenses, and service awards. If there are objections, the Court will consider them. After the hearing, the Court will decide whether to give final approval to the Settlement and the other requests. It is unknown how long these decisions, or decisions on any appeals of them, will take.

Any judgment issued by the Court will be binding on the Settlement Class. The Settlement, if approved by the Court and once appeals, if any, are resolved, will release all claims in the putative class actions against Sandoz.

### 20. DO I HAVE TO ATTEND THE HEARING?

No. Settlement Class Counsel will answer any questions the Court may have. However, you are welcome to attend the hearing at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you filed your written objection on time, to the proper addresses, and it complies with the other requirements provided above, the Court will consider it. You also may pay your own lawyer to attend the hearing, but this is not necessary.

Attendance is not necessary to receive your share of the settlement fund.

## 21. MAY I SPEAK AT THE HEARING?

You may ask the Court for permission to speak at the Fairness Hearing. To do so, you must file your notice by sending a letter via First-Class U.S. Mail titled “Notice of Intention to Appear in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.),” to the Clerk of Court, with copies to the individuals and addresses listed in Question 18 above. (If an attorney is filing the notice on your behalf, your attorney must comply with the Court’s Local Rules, including those that mandate document filings via ECF.)

Be sure to include your name, address, email address, telephone number and signature, and state that you intend to appear at the Fairness Hearing on the EPP Sandoz Settlement. If applicable, include the name, address, email address, and telephone number of your attorney (who must file a Notice of Appearance). Your Notice of Intention to Appear must be filed with the Court so that it is **received** by the Court no later than **May 9, 2025**.

You may not speak at the hearing if you excluded yourself as a Settlement Class Member or do not send a Notice of Intention to Appear.

## GETTING MORE INFORMATION

### 22. HOW DO I GET MORE INFORMATION?

If you have questions about the Settlement or want additional information, you should first review the information posted on the Settlement Website. If you still have questions, you may call the Notice Administrator at 1-877-316-0171 or contact the attorney or law firm identified in Question 16. This notice is only a summary of the proposed Settlement and is qualified in its entirety by the terms of the Settlement Agreement. A copy of the Settlement Agreement is on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106. The Settlement Agreement is also available on the Settlement Website.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK’S OFFICE TO INQUIRE ABOUT THE SETTLEMENT OR THE CLAIMS PROCESS.